210 related articles for article (PubMed ID: 34088739)
1. Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors.
Hurkmans DP; Sassen SDT; de Joode K; Putter L; Basak EA; Wijkhuijs AJM; Joerger M; Debets R; Koch BCP; Van der Leest CH; Schreurs MWJ; van der Veldt AAM; Aerts JGJV; Mathijssen RHJ; Koolen SLW
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088739
[TBL] [Abstract][Full Text] [Related]
2. Life-threatening toxicities upon Pembrolizumab intake: could pharmacokinetics be the bad guy?
Hamimed M; Devillier R; Weiller PJ; Marin C; Schiano JM; Belmecheri N; Etienne-Grimaldi MC; Ciccolini J; Harbi S
Cancer Chemother Pharmacol; 2024 Jun; 93(6):627-632. PubMed ID: 37957436
[TBL] [Abstract][Full Text] [Related]
3. Chronic polyradiculoneuropathy associated with pembrolizumab for bladder cancer.
Kobayashi Y; Iijima K; Kondo Y; Yamamoto K; Sekijima Y
Acta Neurol Belg; 2024 Jun; 124(3):1063-1065. PubMed ID: 38010574
[No Abstract] [Full Text] [Related]
4. Killing a fly with a sledgehammer: Atezolizumab exposure in real-world lung cancer patients.
Marolleau S; Mogenet A; Boeri C; Hamimed M; Ciccolini J; Greillier L
CPT Pharmacometrics Syst Pharmacol; 2023 Nov; 12(11):1795-1803. PubMed ID: 38011601
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of adebrelimab - Support of alternative flat dose regimen in extensive-stage small-cell lung cancer.
Chen P; Zhang Y; Wang Y; Ma K; Shi W; Djebli N; Shen K
CPT Pharmacometrics Syst Pharmacol; 2024 May; ():. PubMed ID: 38711252
[TBL] [Abstract][Full Text] [Related]
6. Baseline and early functional immune response is associated with subsequent clinical outcomes of PD-1 inhibition therapy in metastatic melanoma patients.
Gérard A; Doyen J; Cremoni M; Bailly L; Zorzi K; Ruetsch-Chelli C; Brglez V; Picard-Gauci A; Troin L; Esnault VLM; Passeron T; Montaudié H; Seitz-Polski B
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088741
[TBL] [Abstract][Full Text] [Related]
7. Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid Cancers.
Al-Showbaki L; Nadler MB; Desnoyers A; Almugbel FA; Cescon DW; Amir E
J Cancer; 2021; 12(14):4372-4378. PubMed ID: 34093837
[No Abstract] [Full Text] [Related]
8. Pembrolizumab and Ipilimumab as Second-Line Therapy for Advanced Melanoma.
Huppert LA; Daud AI
J Clin Oncol; 2021 Aug; 39(24):2637-2639. PubMed ID: 34138634
[No Abstract] [Full Text] [Related]
9. Incidence of Infections and Predictors of Mortality During Checkpoint Inhibitor Immunotherapy in Patients With Advanced Lung Cancer: A Retrospective Cohort Study.
Bavaro DF; Pizzutilo P; Catino A; Signorile F; Pesola F; Di Gennaro F; Cassiano S; Marech I; Lamorgese V; Angarano G; Monno L; Saracino A; Galetta D
Open Forum Infect Dis; 2021 Jun; 8(6):ofab187. PubMed ID: 34141817
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer.
Sugawara S; Lee JS; Kang JH; Kim HR; Inui N; Hida T; Lee KH; Yoshida T; Tanaka H; Yang CT; Nishio M; Ohe Y; Tamura T; Yamamoto N; Yu CJ; Akamatsu H; Namba Y; Sumiyoshi N; Nakagawa K
Ann Oncol; 2021 Sep; 32(9):1137-1147. PubMed ID: 34139272
[TBL] [Abstract][Full Text] [Related]
11. A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non-small Cell Lung Cancer.
Garon EB; Spira AI; Johnson M; Bazhenova L; Leach J; Cummings AL; Candia A; Coffman RL; Janatpour MJ; Janssen R; Gamelin E; Chow LQM
Clin Cancer Res; 2021 Aug; 27(16):4566-4573. PubMed ID: 34108179
[TBL] [Abstract][Full Text] [Related]
12. Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis.
Sheng L; Gao J; Xu Q; Zhang X; Huang M; Dai X; Li S; Liu L
Ther Adv Med Oncol; 2021; 13():17588359211018537. PubMed ID: 34104227
[TBL] [Abstract][Full Text] [Related]
13. Sotorasib for Lung Cancers with
Skoulidis F; Li BT; Dy GK; Price TJ; Falchook GS; Wolf J; Italiano A; Schuler M; Borghaei H; Barlesi F; Kato T; Curioni-Fontecedro A; Sacher A; Spira A; Ramalingam SS; Takahashi T; Besse B; Anderson A; Ang A; Tran Q; Mather O; Henary H; Ngarmchamnanrith G; Friberg G; Velcheti V; Govindan R
N Engl J Med; 2021 Jun; 384(25):2371-2381. PubMed ID: 34096690
[TBL] [Abstract][Full Text] [Related]
14. Serum Metabolite Biomarkers Predictive of Response to PD-1 Blockade Therapy in Non-Small Cell Lung Cancer.
Nie X; Xia L; Gao F; Liu L; Yang Y; Chen Y; Duan H; Yao Y; Chen Z; Lu S; Wang Y; Yang C
Front Mol Biosci; 2021; 8():678753. PubMed ID: 34095230
[No Abstract] [Full Text] [Related]
15. Increased serum cholesterol and long-chain fatty acid levels are associated with the efficacy of nivolumab in patients with non-small cell lung cancer.
Karayama M; Inui N; Inoue Y; Yoshimura K; Mori K; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Asada K; Uto T; Fujii M; Matsui T; Matsuura S; Hashimoto D; Toyoshima M; Kusagaya H; Matsuda H; Inami N; Kaida Y; Niwa M; Ito Y; Suda T
Cancer Immunol Immunother; 2022 Jan; 71(1):203-217. PubMed ID: 34091744
[TBL] [Abstract][Full Text] [Related]
16. Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
Moskowitz AJ; Shah G; Schöder H; Ganesan N; Drill E; Hancock H; Davey T; Perez L; Ryu S; Sohail S; Santarosa A; Galasso N; Neuman R; Liotta B; Blouin W; Kumar A; Lahoud O; Batlevi CL; Hamlin P; Straus DJ; Rodriguez-Rivera I; Owens C; Caron P; Intlekofer AM; Hamilton A; Horwitz SM; Falchi L; Joffe E; Johnson W; Lee C; Palomba ML; Noy A; Matasar MJ; Pongas G; Salles G; Vardhana S; Sanin BW; von Keudell G; Yahalom J; Dogan A; Zelenetz AD; Moskowitz CH
J Clin Oncol; 2021 Oct; 39(28):3109-3117. PubMed ID: 34170745
[TBL] [Abstract][Full Text] [Related]
17. First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50.
Descourt R; Chouaid C; Pérol M; Besse B; Greillier L; Bylicki O; Ricordel C; Guisier F; Gervais R; Schott R; Auliac JB; Robinet G; Decroisette C
Future Oncol; 2021 Aug; 17(23):3007-3016. PubMed ID: 34156285
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of pembrolizumab + chemotherapy versus chemotherapy and pembrolizumab monotherapy in first line treatment of NSCLC in the US - updated analyses with additional trial follow-up.
Insinga RP; Feliciano JL; Qiao N; Vandormael K; Zhang Y
J Med Econ; 2021; 24(1):792-805. PubMed ID: 34098842
[TBL] [Abstract][Full Text] [Related]
19. ICI plus chemotherapy prolonged survival over ICI alone in patients with previously treated advanced NSCLC.
Mao S; Zhou F; Liu Y; Yang S; Chen B; Xu J; Wu F; Li X; Zhao C; Wang W; Liu Q; Yu X; Jia K; Shao C; Zhou C; Gao G; Ren S
Cancer Immunol Immunother; 2022 Jan; 71(1):219-228. PubMed ID: 34097116
[TBL] [Abstract][Full Text] [Related]
20. Molecular determinants of response to PD-L1 blockade across tumor types.
Banchereau R; Leng N; Zill O; Sokol E; Liu G; Pavlick D; Maund S; Liu LF; Kadel E; Baldwin N; Jhunjhunwala S; Nickles D; Assaf ZJ; Bower D; Patil N; McCleland M; Shames D; Molinero L; Huseni M; Sanjabi S; Cummings C; Mellman I; Mariathasan S; Hegde P; Powles T
Nat Commun; 2021 Jun; 12(1):3969. PubMed ID: 34172722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
